Hereditary pheochromocytoma-paraganglioma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:29072OMIM:115310C74.1C75.5D35.0
Who is this for?
Show terms as
10Active trials20Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hereditary pheochromocytoma-paraganglioma (also called hereditary PPGL or familial pheochromocytoma-paraganglioma syndrome) is a rare inherited condition that causes tumors to grow in and around certain nerve tissues. Pheochromocytomas are tumors that form in the adrenal glands, which sit on top of the kidneys. Paragangliomas are similar tumors that grow in other parts of the body, such as the neck, chest, or abdomen. These tumors are usually not cancerous, but they can cause serious problems because they release hormones called catecholamines — including adrenaline — into the bloodstream. When these hormones are released in large amounts, they can cause sudden spikes in blood pressure, a racing heart, heavy sweating, and severe headaches. Over time, uncontrolled high blood pressure can damage the heart and other organs. Some people have no symptoms at all and are only diagnosed because a family member was found to have the condition. Treatment usually involves surgery to remove the tumor, which can be curative in many cases. Medications are used before surgery to control blood pressure and reduce the risk of dangerous complications. Because this condition is hereditary, family members of someone diagnosed should also be tested. Long-term follow-up is important since new tumors can develop over time, and a small number of tumors can spread to other parts of the body.

Also known as:

Key symptoms:

Sudden, severe headachesVery high blood pressure, sometimes in sudden spikesRapid or pounding heartbeat (palpitations)Heavy sweating, often without a clear reasonFeeling anxious or having a sense of panicPale skinTrembling or shakingNausea or vomitingFeeling lightheaded or dizzyUnexplained weight lossFeeling very tired or weakA lump or mass in the neck or abdomen that can be felt or seen on imaging

Clinical phenotype terms (41)— hover any for plain English
ParagangliomaHP:0002668Extraadrenal pheochromocytomaHP:0006737Adrenal pheochromocytomaHP:0006748Glomerular sclerosisHP:0000096Episodic paroxysmal anxietyHP:0000740Episodic hyperhidrosisHP:0001069Hypertensive retinopathyHP:0001095Recurrent paroxysmal headacheHP:0002331Hypertension associated with pheochromocytomaHP:0002640Paraganglioma of head and neckHP:0002864Elevated urinary norepinephrine levelHP:0003345Positive regitine blocking testHP:0003574
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Oct 2025Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting Tumors

Central Hospital, Nancy, France

TrialNOT YET RECRUITING
Aug 2025[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

National Cancer Institute (NCI) — PHASE1

TrialRECRUITING
May 2025Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma

Sun Yat-sen University — PHASE2

TrialNOT YET RECRUITING
Jun 2024Using the EHR to Advance Genomic Medicine Across a Diverse Health System

University of Pennsylvania — NA

TrialRECRUITING
Jun 2024Hereditary Pheochromocytoma Assessment of Tumour Immunologies

Radboud University Medical Center

TrialRECRUITING
Dec 2023Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

University College, London — PHASE2

TrialNOT YET RECRUITING
Oct 2023Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study

Rigshospitalet, Denmark

TrialNOT YET RECRUITING
Jan 2023The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

Seoul National University Hospital — PHASE4

TrialRECRUITING
Jul 2022Prognostic's Factors of Head and Neck Paragangliomas Evolution

Hospices Civils de Lyon

TrialACTIVE NOT RECRUITING
Jul 2022Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI) — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Hereditary pheochromocytoma-paraganglioma.

10 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

10 recruitingView all trials with filters →
Phase 41 trial
The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
Phase 4
Actively Recruiting
PI: Su-Jin Kim, M.D., Ph.D (Seoul National University Hospital) · Sites: Seoul · Age: 1970 yrs
Phase 21 trial
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
Phase 2
Active
PI: A P Chen (National Cancer Institute LAO) · Sites: Bethesda, Maryland; Bethesda, Maryland · Age: 1299 yrs
Phase 12 trials
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Phase 1
Actively Recruiting
PI: Frank I Lin, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 18120 yrs
Diagnosis of Pheochromocytoma
Phase 1
Actively Recruiting
PI: Catherine M Gordon, M.D. (Eunice Kennedy Shriver National Institute of Child) · Sites: Bethesda, Maryland · Age: 3120 yrs
N/A3 trials
Multicenter Pheochromocytoma and Paraganglioma Evaluation
N/A
Actively Recruiting
PI: Felix Beuschlein, M.D. (University of Zurich) · Sites: Zurich · Age: 599 yrs
Project: Every Child for Younger Patients With Cancer
N/A
Actively Recruiting Prior treatment eligible
PI: Douglas S Hawkins (Children's Oncology Group) · Sites: Birmingham, Alabama; Mobile, Alabama +18 more · Age: 025 yrs
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
N/A
Actively Recruiting
PI: Katherine L Nathanson, MD (University of Pennsylva) · Sites: Philadelphia, Pennsylvania · Age: 1899 yrs
Other3 trials
Hereditary Pheochromocytoma Assessment of Tumour Immunologies
Actively Recruiting
PI: Margo Dona, PhD (Radboud University Medical Center) · Sites: Nijmegen, Gelderland · Age: 1899 yrs
Prognostic's Factors of Head and Neck Paragangliomas Evolution
Active
· Sites: Bron · Age: 1899 yrs
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Actively Recruiting
PI: Patricia L Dahia, MD, PhD (The University of Texas Health Science Center at S) · Sites: San Antonio, Texas

Specialists

20 foundView all specialists →
MP
Marieke de Laat, M.D. PhD
Specialist
PI on 1 active trial
RP
Romana Netea-Maier, M.D. PhD
Specialist
PI on 1 active trial
MP
Margo Dona, PhD
Specialist
PI on 1 active trial
HP
Henri Timmers, M.D. PhD
Specialist
PI on 1 active trial
VM
Vincent Rohmer, MD
Specialist
PI on 1 active trial
WM
W. Marston Linehan, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 6 active trials
KM
Kim E. Nichols, MD
Memphis, Tennessee
Specialist

Rare Disease Specialist

PI on 2 active trials
LP
Laura C Hernández Ramírez, MD, PhD
Mexico City, Mexico City
Specialist

Rare Disease Specialist

PI on 1 active trial
MP
Marcelo Serra, PhD
Buenos Aires, Buenos Aires
Specialist

Rare Disease Specialist

PI on 1 active trial
MP
Maria Lourdes Posadas Martinez, PhD
Specialist
PI on 1 active trial
AG
Agustin Garcia
MISSOULA, MT
Specialist
PI on 5 active trials108 Hereditary pheochromocytoma-paraganglioma publications
PP
Patricia L Dahia, MD, PhD
Specialist
PI on 2 active trials
SM
Sjoukje Oosting, MD
Specialist
PI on 2 active trials
AP
Anne-Paule Gimenez-Roqueplo, MD, PhD
Specialist
PI on 2 active trials
CP
Christine A Pratilas
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 1 active trial
CM
Christian A Nebiker, PD Dr. med.
Specialist
PI on 1 active trial
VM
Vivek Subbiah, MD
STANFORD, CA
Specialist
PI on 2 active trials
RM
Raymond Bergan, MD
CHICAGO, IL
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hereditary pheochromocytoma-paraganglioma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hereditary pheochromocytoma-paragangliomaForum →

No community posts yet. Be the first to share your experience with Hereditary pheochromocytoma-paraganglioma.

Start the conversation →

Latest news about Hereditary pheochromocytoma-paraganglioma

Disease timeline:

New recruiting trial: Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

A new clinical trial is recruiting patients for Hereditary pheochromocytoma-paraganglioma

New recruiting trial: Hereditary Pheochromocytoma Assessment of Tumour Immunologies

A new clinical trial is recruiting patients for Hereditary pheochromocytoma-paraganglioma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which gene mutation do I have, and what does that mean for my risk of developing new tumors or malignant disease?,How often do I need surveillance testing, and what does that involve?,Which medications, supplements, or foods should I avoid because they could trigger a dangerous episode?,Should my children, siblings, or parents be tested, and how do I arrange that?,What are the warning signs of a hypertensive crisis, and what should I do if one happens?,Am I a candidate for surgery, and what preparation is needed beforehand?,Are there clinical trials or specialized centers I should consider for my care?

Common questions about Hereditary pheochromocytoma-paraganglioma

What is Hereditary pheochromocytoma-paraganglioma?

Hereditary pheochromocytoma-paraganglioma (also called hereditary PPGL or familial pheochromocytoma-paraganglioma syndrome) is a rare inherited condition that causes tumors to grow in and around certain nerve tissues. Pheochromocytomas are tumors that form in the adrenal glands, which sit on top of the kidneys. Paragangliomas are similar tumors that grow in other parts of the body, such as the neck, chest, or abdomen. These tumors are usually not cancerous, but they can cause serious problems because they release hormones called catecholamines — including adrenaline — into the bloodstream. Wh

How is Hereditary pheochromocytoma-paraganglioma inherited?

Hereditary pheochromocytoma-paraganglioma follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Hereditary pheochromocytoma-paraganglioma?

Yes — 10 recruiting clinical trials are currently listed for Hereditary pheochromocytoma-paraganglioma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Hereditary pheochromocytoma-paraganglioma?

20 specialists and care centers treating Hereditary pheochromocytoma-paraganglioma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.